Shaftel, Herbert E.; Selman, David
June 1959
Angiology;Jun1959, Vol. 10 Issue 3, p131
Academic Journal
Examines the ability of sublingual heparin to clarify lipemic serum in a series of 36 patients under an acute experimental design. Determination of a base line curve of the serum turbidity after the ingestion of a standard fat test meal and after the administration of sublingual heparin; Inability to detect any effect of sublingual heparin on blood coagulation; Clarification of lipemic serum in parents after fat ingestion and therapy.


Related Articles

  • THE EFFECT OF REPOSITORY HEPARIN UPON LIPOPROTEIN PATTERNS IN HUMAN BEINGS. Loewe, Leo; Richmond, Gilbert; Brown, B. S. Raymond; Lasser, Richard P.; Cohen, Clifford; Cox, Herald // Angiology;Aug1953, Vol. 4 Issue 4, p295 

    In this study the marked effect of repository heparin upon the lipoprotein pattern of human beings has been demonstrated. It thus constitutes a confirmation of the initial observation of Graham et al. (7) in this regard. We have observed that the most pronounced effect is upon the lipoproteins...

  • Orally Ingested Heparin Is Absorbed in Humans. Engelberg, Hyman // Clinical & Applied Thrombosis/Hemostasis;Fall1995, Vol. 1 Issue 4, p283 

    It has been accepted for many years that orally ingested heparin is not absorbed. Recent evidence has shown that heparin placed in the stomach of rats is very rapidly absorbed and that it also quickly and almost completely attaches to the vascular endothelium and prevents jugular vein...

  • Flolan.  // Royal Society of Medicine: Medicines;2002, p249 

    The article provides information on Flolan, a proprietary, prescription-only preparation of the antiplatelet aggregation drug epoprostenol. It can be used to prevent formation of clots, for example, in conjunction with heparin in kidney dialysis, and is available in a form for intravenous infusion.

  • Is enoxaparin the superior low molecular weight heparin? Magill-Lewis, Jillene // Drug Topics;2/23/2004, Vol. 148 Issue 4, p40 

    Compares the effectiveness of the low molecular weight heparins enoxaparin and unfractionated heparin. Studies showing the superiority of enoxaparin over unfractionated heparin; Significant reductions in death, myocardial infarction, angina and the need for revascularization in the patients...

  • Management of Thrombotic and Cardiovascular Disorders in the New Millenium. Fareed, Jawed; Hoppensteadt, Debra A.; Bick, Rodger L. // Clinical & Applied Thrombosis/Hemostasis;Apr2003, Vol. 9 Issue 2, p101 

    Anticoagulants and antithrombotic drugs have played a key role in the prophylaxis, treatment and surgical/interventional management of thrombotic and cardiovascular disorders. There are several newer drugs which are currently developed for the anticoagulant management of cardiovascular diseases...

  • POINT / COUNTER. Weitz, Jeffrey; Liebman, Howard A. // Hem/Onc Today;3/25/2008, Vol. 9 Issue 5, p11 

    This article presents a debate on whether Factor IIa (thrombin) or Factor Xa appears to be a better target for oral anticoagulant therapies. One person contends that the whole idea with Factor Xa is that it only convert prothrombin to thrombin, whereas thrombin has all the other effects. Another...

  • Anticoagulation in venous thrombosis. Schulman, Sam // Journal of the Royal Society of Medicine;Nov1996, Vol. 89 Issue 11, p624 

    Major studies addressing various aspects of the treatment of deep vein thrombosis are reviewed. It has lately been demonstrated that heparin should be dosed according to body weight and is preferably given as subcutaneous injections twice daily. Alternatively, low-molecular-weight heparins may...

  • Oral Anticoagulants in Development: Focus on Thromboprophylaxis in Patients Undergoing Orthopaedic Surgery. Eriksson, Bengt I.; Quinlan, Daniel J. // Drugs;2006, Vol. 66 Issue 11, p1411 

    Current anticoagulant provision is dominated by parenteral heparin and oral warfarin, which act by inhibiting several steps of the coagulation pathway indirectly. Recent research efforts have focused on the identification of small molecule inhibitors of the coagulation enzymes as novel therapies...

  • Comparison of ACT point-of-care measurements: repeatability and agreement. Bosch, Y. P. J.; Ganushchak, Y. M.; de Jong, D. S. // Perfusion;Jan2006, Vol. 21 Issue 1, p27 

    Background: Accurate control of heparin anticoagulation is necessary during all stages of cardiopulmonary bypass (CPB). The activated clotting time, first described by Hattersley in 1966, is mostly used for determination of anticoagulation. Either celite or kaolin are used as activators. An ACT...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics